These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 24325305

  • 1. Does the calcineurin inhibitor have influence on cytomegalovirus infection in heart transplantation?
    Rodríguez-Serrano M, Sánchez-Lázaro I, Almenar-Bonet L, Martínez-Dolz L, Portolés-Sanz M, Rivera-Otero M, Salvador-Sanz A.
    Clin Transplant; 2014 Jan; 28(1):88-95. PubMed ID: 24325305
    [Abstract] [Full Text] [Related]

  • 2. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
    [Abstract] [Full Text] [Related]

  • 3. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L, Euro-SPK Study Group.
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [Abstract] [Full Text] [Related]

  • 4. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kisilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO.
    Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
    [Abstract] [Full Text] [Related]

  • 5. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S, Moal V, Gaudart J, Indreies M, Purgus R, Dussol B, Zandotti C, Berland Y, Vacher-Coponat H.
    Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
    [Abstract] [Full Text] [Related]

  • 6. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
    Guethoff S, Meiser BM, Groetzner J, Eifert S, Grinninger C, Ueberfuhr P, Reichart B, Hagl C, Kaczmarek I.
    Transplantation; 2013 Feb 27; 95(4):629-34. PubMed ID: 23423270
    [Abstract] [Full Text] [Related]

  • 7. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 8. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis.
    Beam E, Lesnick T, Kremers W, Kennedy CC, Razonable RR.
    Clin Transplant; 2016 Mar 15; 30(3):270-8. PubMed ID: 26701733
    [Abstract] [Full Text] [Related]

  • 9. Cyclosporine Versus Tacrolimus: Which Calcineurin Inhibitor Has Influence on Cytomegalovirus Infection in Cardiac Transplantation?
    Bond MMK, Bond MMK, Sehn A, Dias VH, Said TL, Dos Santos CC, Finger MA, Santos AMG, Neto JMR.
    Transplant Proc; 2018 Apr 15; 50(3):809-814. PubMed ID: 29661443
    [Abstract] [Full Text] [Related]

  • 10. Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy.
    Werzowa J, Schwaiger B, Hecking M, Strassl R, Schmaldienst S, Böhmig GA, Genser B, Säemann MD.
    Clin Transplant; 2015 Dec 15; 29(12):1230-8. PubMed ID: 26458731
    [Abstract] [Full Text] [Related]

  • 11. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
    Slifkin M, Ruthazer R, Freeman R, Bloom J, Fitzmaurice S, Fairchild R, Angelis M, Cooper J, Barefoot L, Rohrer R, Snydman DR.
    Liver Transpl; 2005 Dec 15; 11(12):1597-602. PubMed ID: 16315314
    [Abstract] [Full Text] [Related]

  • 12. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine.
    Castel MA, Farrero M, Vallejos I, Cardona M, Regueiro A, Pérez-Villa F.
    Transplant Proc; 2011 Dec 15; 43(6):2244-6. PubMed ID: 21839245
    [Abstract] [Full Text] [Related]

  • 13. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.
    Transpl Infect Dis; 2015 Apr 15; 17(2):163-73. PubMed ID: 25661673
    [Abstract] [Full Text] [Related]

  • 14. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.
    Potena L, Grigioni F, Magnani G, Lazzarotto T, Musuraca AC, Ortolani P, Coccolo F, Fallani F, Russo A, Branzi A.
    J Heart Lung Transplant; 2009 May 15; 28(5):461-7. PubMed ID: 19416774
    [Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D, Nguyen MH, Kwak EJ, Silveira FP, Vadnerkar A, Pilewski J, Crespo M, Toyoda Y, Bermudez C, Clancy CJ.
    J Heart Lung Transplant; 2010 Sep 15; 29(9):1014-20. PubMed ID: 20598582
    [Abstract] [Full Text] [Related]

  • 16. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
    Jewani PK, Pouch SM, Kissling KT.
    Clin Transplant; 2018 Nov 15; 32(11):e13420. PubMed ID: 30290013
    [Abstract] [Full Text] [Related]

  • 17. A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation.
    Sánchez-Lázaro IJ, Almenar L, Martínez-Dolz L, Buendía-Fuentes F, Agüero J, Navarro-Manchón J, Vicente JL, Salvador A.
    Clin Transplant; 2011 Nov 15; 25(4):606-13. PubMed ID: 20682020
    [Abstract] [Full Text] [Related]

  • 18. Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus.
    Fuchs U, Klein S, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Ann Transplant; 2014 Jun 23; 19():300-4. PubMed ID: 24953848
    [Abstract] [Full Text] [Related]

  • 19. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.
    Transplant Proc; 2007 Sep 23; 39(7):2228-30. PubMed ID: 17889146
    [Abstract] [Full Text] [Related]

  • 20. The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation.
    Sheng L, Jun S, Jianfeng L, Lianghui G.
    Clin Transplant; 2015 Jun 23; 29(6):555-9. PubMed ID: 25851741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.